Unither Pharmaceuticals and Needle Concept®have announced a strategic partnership to develop a new generation of needles compatible with the Euroject® system

Unither Pharmaceuticals and Needle Concept join forces to improve drug injection

Unither Pharmaceuticals and Needle Concept® - both winners of the French Government's Capacity Building program - have announced a strategic partnership to develop a new generation of needles compatible with the Euroject® system. The aim of this collaboration is to offer an optimised single-dose injection solution that is safer and easier to use, meeting the requirements of healthcare professionals and patients alike.

Through this alliance, the two companies are combining their industrial and technological expertise to offer a ready-to-use injection device that is effective and compliant with international standards.

Unither Pharmaceuticals

With 30 years' experience and an unwavering commitment to innovation, Unither Pharmaceuticals, a French company, has established itself as a world leader in the contract manufacture of pharmaceutical products.

An innovative delivery device

Developed by Unither Pharmaceuticals, Euroject® is a single-dose delivery system using Blow-Fill-Seal (BFS) technology. This approach makes it possible to mass-produce sterile, pre-filled single-dose units, facilitating the administration of injectable drugs.

The benefits of Euroject® :

• Enhanced safety: reduced risk of infection and dosing errors

• Ease of use: designed to be used quickly, without complex handling.

• Optimised production: large-scale manufacturing, reducing costs and improving accessibility.

• Compliance with international standards: meets the requirements of health agencies and WHO recommendations.

With the addition of a needle specifically developed by Needle Concept®, combined with single-dose solutions developed by Unither Pharmaceuticals, the device becomes a complete solution for administering injectable medicines.

Large-scale industrial production

Unither Pharmaceuticals is increasing its industrial capacity by expanding its Amiens site to include a production unit specifically dedicated to Euroject® and injectable vaccines. This expansion will enable us to achieve the following production targets:

• 5 filling lines installed in 2 phases, 3 then 2. Over one billion doses produced per year.

• An industrial site designed to optimise the production of injectable devices.

Thanks to this new infrastructure, the needle developed by Needle Concept® can be efficiently integrated into the Euroject® production chain.

Needle Concept: Fluid delivery expertise and industrial capacity tailored to project needs

Needle Concept is a French company specialising in the design and manufacture of innovative solutions for the administration of medical fluids. Its expertise covers the entire development of high-precision needles, with recognised know-how in the optimisation of injection systems.

As part of this partnership, Needle Concept® brings its expertise in fluid delivery and its ability to work to measure to design a needle specifically adapted to the Euroject® system, guaranteeing fluid, safe and effective injection.

To meet growing market demand and support the industrialisation of the project, Needle Concept® is currently completing the construction of a new factory in the Landes region, near Biarritz, to boost its needle production capacity.

An infrastructure designed for excellence:

• Large-scale production capacity to meet the needs of pharmaceutical laboratories.

• Three optimised production lines to guarantee needle quality and precision.

• An industrial site designed to optimise the production of injectable devices.

• A capacity of over 500 million needles manufactured per year.

This plant will play a major role in the implementation of the project, ensuring manufacturing capacity in line with the volumes expected for the Euroject® device.

A positive impact on public health

The combination of Euroject® technology and the dedicated Needle Concept® needle brings significant improvements in several areas:

• Optimisation of vaccination campaigns: Euroject® is particularly well suited to mass vaccination campaigns, where speed and safety are essential.

• Facilitating access to treatment in developing countries: Thanks to its simple design and controlled cost, this device makes it possible to administer injectable treatments in contexts where medical resources are limited.

• Reduced medical waste: The use of a pre-filled, single-dose device limits the amount of waste generated by traditional syringes.

• Safer medical care: The pre-filled system reduces the risk of errors and contamination, ensuring better patient care.

A strategic French partnership for innovation in healthcare

Unither Pharmaceuticals and Needle Concept are both winners of the AMI Capacity Building programme, initiated by the French government to strengthen French industrial capabilities in the fight against COVID-19. By supporting these strategic initiatives, the French government aims to reduce dependence on imports, secure supply chains and boost the country's industrial ecosystem in the interests of our industrial sovereignty in the healthcare sector.

This recognition illustrates the strategic importance of their investments, while affirming their commitment to national sovereignty, the reindustrialisation of France and innovation in the field of medical injections.

The agreement between Unither Pharmaceuticals and Needle Concept marks a major step forward in the field of injection devices. It combines innovative technology, French industrial production and ease of use, bringing immediate benefits for healthcare professionals and comfort for patients.